Literature DB >> 22986289

Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.

Katherine P Liao1, Daniel H Solomon.   

Abstract

Multiple studies demonstrate an increased cardiovascular (CV) risk associated with RA compared with the general population. While part of this risk appears to be mediated by RA-specific factors, such as long-term inflammation, traditional CV comorbidities also play an important role. We review evidence from previous studies of the relationship between RA and traditional CV comorbidities such as dyslipidaemia, obesity, insulin resistance and diabetes, hypertension, cigarette smoking and physical inactivity. We examine the prevalence and consider the effect of inflammation and RA treatments on these risk factors. Finally, we discuss three widely used CV risk estimators, the Framingham Risk Score, Reynolds Risk Score and the Systematic Coronary Risk Evaluation, and their performance in patients with RA. The traditional CV risk factors that appear to differ significantly between RA cases and controls include insulin resistance, abnormal fat distribution, cigarette smoking and lack of physical activity. Dyslipidaemia, diabetes and hypertension may also be elevated in RA; however, the evidence is conflicting. Overall, we found that the majority of information regarding CV risk factors in RA stems from data collected as covariates for studies on CV disease. A gap in knowledge exists regarding detailed information on individual risk factors in RA, their prevalence and modifications that occur as a result of inflammation or treatment. More studies are needed to develop methods for accurate CV risk estimation in RA.

Entities:  

Mesh:

Year:  2012        PMID: 22986289      PMCID: PMC3521444          DOI: 10.1093/rheumatology/kes243

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  81 in total

1.  Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis.

Authors:  Daniel H Solomon; Thorvardur Jon Love; Claire Canning; Sebastian Schneeweiss
Journal:  Ann Rheum Dis       Date:  2010-06-28       Impact factor: 19.103

2.  Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity.

Authors:  Daniel H Solomon; Joel Kremer; Jeffrey R Curtis; Marc C Hochberg; George Reed; Peter Tsao; Michael E Farkouh; Soko Setoguchi; Jeffrey D Greenberg
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

Review 3.  A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis.

Authors:  Eduardo Nicolas Pollono; Maria A Lopez-Olivo; Juan Antonio Martinez Lopez; Maria E Suarez-Almazor
Journal:  Clin Rheumatol       Date:  2010-04-10       Impact factor: 2.980

4.  Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics.

Authors:  Jon T Giles; Matthew Allison; Roger S Blumenthal; Wendy Post; Allan C Gelber; Michelle Petri; Russell Tracy; Moyses Szklo; Joan M Bathon
Journal:  Arthritis Rheum       Date:  2010-11

5.  Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study.

Authors:  Christine K Iannaccone; Yvonne C Lee; Jing Cui; Michelle L Frits; Roberta J Glass; Robert M Plenge; Daniel H Solomon; Michael E Weinblatt; Nancy A Shadick
Journal:  Rheumatology (Oxford)       Date:  2010-09-16       Impact factor: 7.580

6.  Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study.

Authors:  Maurizio Mazzantini; Rosaria Talarico; Marica Doveri; Arianna Consensi; Massimiliano Cazzato; Laura Bazzichi; Stefano Bombardieri
Journal:  J Rheumatol       Date:  2010-09-15       Impact factor: 4.666

7.  Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.

Authors:  Elena Myasoedova; Cynthia S Crowson; Hilal Maradit Kremers; Veronique L Roger; Patrick D Fitz-Gibbon; Terry M Therneau; Sherine E Gabriel
Journal:  Ann Rheum Dis       Date:  2011-01-07       Impact factor: 19.103

8.  Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study.

Authors:  A Jamnitski; I M Visman; M J L Peters; B A C Dijkmans; A E Voskuyl; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2010-05-24       Impact factor: 19.103

Review 9.  Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.

Authors:  Jasvinder A Singh; Saba Beg; Maria Angeles Lopez-Olivo
Journal:  J Rheumatol       Date:  2010-10-15       Impact factor: 4.666

10.  Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases.

Authors:  Olaf Schultz; Frank Oberhauser; Jasemine Saech; Andrea Rubbert-Roth; Moritz Hahn; Wilhelm Krone; Matthias Laudes
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

View more
  52 in total

1.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

2.  Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.

Authors:  Mai Duong; Abdelilah Abouelfath; Regis Lassalle; Cécile Droz; Patrick Blin; Nicholas Moore
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

3.  Insulin resistance is associated with increased concentrations of NT-proBNP in rheumatoid arthritis: IL-6 as a potential mediator.

Authors:  William S Bradham; Michelle J Ormseth; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

Review 4.  Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps.

Authors:  Thomas Zegkos; George Kitas; Theodoros Dimitroulas
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-30       Impact factor: 5.346

5.  [Treatment of cardiovascular risk factors].

Authors:  K Krüger
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

6.  Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China.

Authors:  Chun Li; X R Wang; H J Ji; X Y Zhang; X F Li; L Z Wang; C H Wang; Y F Wang; Rong Yang; G C Wang; Xin Lu; Ping Zhu; L N Chen; H T Jin; J T Liu; X Y Liu; Lin Sun; H Y Chen; Ping Wei; J X Wang; L F Cui; Rong Shu; B L Liu; Z L Zhang; G T Li; Z B Li; Jing Yang; J F Li; Bin Jia; F X Zhang; J M Tao; S L Han; J Y Lin; M Q Wei; X M Liu; Dan Ke; S X Hu; Cong Ye; X Y Yang; Hao Li; C B Huang; Ming Gao; Bei Lai; X F Li; L J Song; Yi Wang; X Y Wang; Y D Tang; Yin Su; Rong Mu; Z G Li
Journal:  Clin Rheumatol       Date:  2017-03-24       Impact factor: 2.980

7.  The role of rheumatologists vis-à-vis assessment of traditional cardiovascular risk factors in rheumatoid arthritis.

Authors:  Yael Luck; Murray Baron; Sonia Bardakjian; Laeora Berkson; Maura Buchignani; Sabrina Fallavolita; Frédérique Giac; Geneviève Gyger; Solène Tatibouet; Marie Hudson
Journal:  Clin Rheumatol       Date:  2014-02-15       Impact factor: 2.980

8.  Serum level of neopterin is not a marker of disease activity in treated rheumatoid arthritis patients.

Authors:  Dalia El-Lebedy; Jihan Hussein; Ingy Ashmawy; Asmaa M Mohammed
Journal:  Clin Rheumatol       Date:  2016-10-03       Impact factor: 2.980

Review 9.  Co-morbidity index in rheumatoid arthritis: time to think.

Authors:  Yasser El Miedany
Journal:  Clin Rheumatol       Date:  2015-10-26       Impact factor: 2.980

Review 10.  Sex and Cardiovascular Involvement in Inflammatory Joint Diseases.

Authors:  Santos Castañeda; Carlos González-Juanatey; Miguel A González-Gay
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.